SciSparc-Clearmind MDMA-PEA Patent Published as FDA Finalizes Psychedelic Guidance
SPRC has more than doubled off its 52-week low of $2.98.
Summary
SciSparc's subsidiary NeuroThera and Clearmind Medicine advanced their collaboration with the U.S. publication of a patent application covering MDMA combined with N-acylethanolamines like PEA for PTSD, anxiety, and eating disorders. The application includes claims on PEA's potential to enhance MDMA's therapeutic potency, reduce dosing, mitigate side effects, and broaden the therapeutic window. This is the thirteenth published patent application from the collaboration, expanding the joint IP portfolio. The publication coincides with the FDA's July 14, 2026 final guidance on psychedelic drug development, which explicitly includes MDMA and provides regulatory context for the combination. For a micro-cap company with a market cap under $4 million, this IP milestone and regulatory tailwind are material to the investment thesis, though no clinical data or commercial terms are disclosed. Clearmind Medicine (CMND) is the collaboration partner and also benefits from the joint IP.
At the time of this announcement, SPRC was trading at $7.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $2.98 to $80.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.